Medivir AB to Hold Conference Call and Breakfast Meeting to Discuss TMC435 Data Presented at the 61st AASLD Meeting

2010-10-29

HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir AB (OMX: MVIR), a research-based specialty pharmaceutical company focused on infectious diseases will hold a conference call for analysts and investors and a breakfast meeting in Boston, USA, for US based investors, analysts and media on Tuesday 2nd November 2010. Both events will discuss Medivir’s lead development product TMC435, a once-daily hepatitis C protease inhibitor in phase 2b development, which is being jointly developed by Medivir and Tibotec Pharmaceuticals.

机构